Irm LLC

Novartis Ag

Other

Huawei Technologies Co., Limited

Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Tsinghua University

Electric Power Research Institute Incorporated

Baoshan Iron & Steel Co., Ltd.

Zhuhai United Laboratories Co., Ltd.

Guangdong Electronics Industry Institute Ltd.

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

Xiaolin Li

Valentina Molteni

Juliet Nabakka

Haiying He

Jon Christopher Loren

Xiaodong Liu

Zhi Luo

Donatella Chianelli

Shuhui Chen

Jian Li

Feng Li

Tao Li

Peng Li

Zheng Wang

Vince S Yeh

Weidong Li

Wen Ting Liu

Yi Liu

Pascal Furet

Donald Karanewsky

Yuan Chen

Bao Vinh Nguyen

Vito Guagnano

Shifeng Pan

Hank Michael James Petrassi

Peichao Lu

John Wityak

Zachary Kevin Sweeney

Kai Zhou

Jiping Fu

Aregahegn Yifru

Robert E Babine

Pingda Ren

Yan Li

Qian Zhao

Yun He

Bo Wang

Xiaodong Wang

Yi Xie

Javier De Vicente Fidalgo

Werner Breitenstein

Yu Deng

David C Tully

Zhigan Jiang

Robert Epple

Shuli You

Wenhua Li

Chunlai Feng

Xutao Gao

Dakun Qin

Songliang Wu

Yuhe Wang

Alexey A Rivkin

Enrique Saez

Wosenu Mergo

Bruno Tse

Xiaojing Michael Wang

Taebo Sim

Mihai Azimioara

Subramanian Karur

Meiliana Tjandra

Xiaofei Wang

Yaxun Yang

Yizhi Liu

Hualing Xiao

Yandong Wang

Shaolong Wang

Fei Hao

Lele Yang

Beth Anaclerio

Zuosheng Liu

Cheng Hu

Songchun Jiang

Fang Liang

Naomi S Rajapaksa

Liang Shen

Daniel Mutnick

Shishu Xie

Huawei Zhang

Yongjie Yang

Hongxu Hei

Xingxing Wang

Aihua Ma

Xiandong Liu

David Archer Ellis

Timothy M Ramsey

Liang Zou

Christopher Cow

Folkert Reck

Christopher Becker

Jianhua Xia

Yu Tan

Guohua Yang

Zongbin Li

Zhidong Jia

Yongjin Xu

Zhiwei Xu

Qiang Yue

Hua Qin

Embodiments of the present invention relate to a call record synchronization method, a cloud platform, and a terminal. The method includes: detecting, by a first terminal, an input operation for requesting to display a call record; and after the first terminal detects the input operation, displaying, by the first terminal, a merged call record, where the merged call record is a call record obtained after merging of a call record of the first terminal and a call record of a second terminal, and the merged call record includes a device identifier of the first terminal and/or a device identifier of the second terminal. According to the embodiments of the present invention, a user can use the merged call record to identify call answering or making statuses on a plurality of terminals, without querying a plurality of call records. This improves user experience.

Call record synchronization method, cloud platform, and terminal

Film applicator

A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound

A profile download method includes a primary device obtaining an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID. The primary device receives the profile download information from the mobile operator server and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and where the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Profile download method and device

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. 

SSAO inhibitor

The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

Crystal form of lanosterol prodrug compound and application thereof

A call record synchronization method includes detecting, by a first terminal, an input operation for requesting to display a call record. The method further includes, after the first terminal detects the input operation, displaying, by the first terminal, a merged call record, where the merged call record is a call record obtained after merging of a call record of the first terminal and a call record of a second terminal. The merged call record includes a device identifier of the first terminal and/or a device identifier of the second terminal.

This application relates to the field of communications technologies, and in particular, to a profile download technology. In a profile download method, a primary device obtains an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID; receives the profile download information from the mobile operator server; and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Antiviral pyridopyrazinedione compounds

Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, and the use of same in the preparation of a drug for treating or preventing various conditions associated with FXR. 

Crystalline or amorphous form of steroid derivative FXR agonist, preparation method therefor and use thereof

The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for preparing a compound of formula I, comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, obtaining a compound of formula 11 from a reaction of the compound of formula 10, and obtaining the compound of formula I from a reaction of the compound of formula 11, as well as the intermediates used, the methods for preparing the intermediates and the use of the intermediates. The reaction conditions of the preparation method are mild, and some of the steps can convert multiple groups simultaneously, thereby effectively shortening the sequence of steps. The preparation method is suitable for industrialized production. 

Method for preparing steroid derivative FXR agonist

Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Crystal form of orexin receptor antagonist compound, and preparation method and application thereof

Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Growing community of inventors

San Diego, CA, United States of America

Xiaolin Li